BERKELEY, Calif., Oct. 30 /PRNewswire/ -- Aerovance Inc. today announced the promotion of Anthony M. Rimac to vice president and chief financial officer.
Rimac, 44, previously served as Aerovance’s vice president of finance. He reports to Mark L. Perry, the company’s president and chief executive officer.
“We anticipate achieving several important milestones in 2008 that will propel Aerovance to the next level,” Perry said. “We are tracking toward a strategic partnership for our asthma drug, Aerovant, which will enter Phase IIb early next year. We also expect to be in the clinic with our eczema product, Aeroderm, toward the end of the year. We anticipate adding significant value through these activities. Tony’s extensive experience and knowledge of the healthcare industry will be essential in building the company toward an initial public offering.”
Prior to joining Aerovance in 2005, Rimac was the vice president of finance with Artemis Medical Inc., where he led the sale of the company to Johnson & Johnson. He was also involved in a number of private equity and debt financings. Before this, he was vice president of finance and administration with Aesculap Inc., a division of the B|Braun Group of Companies, where he was responsible for finance, information technology and facilities functions. He was also the director of financial planning and analysis with Aradigm Corp.
Rimac holds an M.B.A. from Santa Clara University and a bachelor’s degree in business economics from the University of California, Santa Barbara. He is a certified public accountant.
Aerovance Inc. is a Berkeley, Calif.-based biopharmaceutical company focused on the development and commercialization of breakthrough therapies for the treatment of respiratory and inflammatory diseases. For more information, visit http://www.aerovance.com.
CONTACT: Tracey Milani, tracey.milani@russopartnersllc.com, or David
Schull, david.schull@russopartnersllc.com, both of Russo Partners,
+1-619-814-3511, for Aerovance Inc.
Web site: http://www.aerovance.com/
